Home | Welcome to Contract Pharma   
Last Updated Tuesday, September 30 2014
Print RSS Feed

Financial Report: WuXi PharmaTech



By Kristin Brooks



Published March 6, 2014
Related Searches: Manufacturing Development
WuXi PharmaTech
 
4Q Revenues: $157.2 million (+25%)

4Q Earnings: $32.9 million (+38%)

FY Revenues: $578.1 million (+16%)

FY Earnings: $114.6 million (+32%)

Comments: Laboratory Services revenue in the quarter grew 15% to $119.4 million, driven by drug discovery and development services, with China-based revenues up 18% to $95.8 million, and U.S.-based revenues up 6% to $23.6 million. Manufacturing Services revenue was up 73% to $37.8 million, driven by strong demand in both research manufacturing and commercial manufacturing compared to 4Q12.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On